Production (Stage)
Maze Therapeutics, Inc.
MAZE
$12.93
-$0.41-3.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Net Income | -32.79M | -29.58M | -24.75M | -32.49M | |
| Total Depreciation and Amortization | 684.00K | 705.00K | 788.00K | 950.00K | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | 4.01M | 5.39M | 5.99M | 7.86M | |
| Change in Net Operating Assets | -1.43M | 1.03M | -5.23M | 249.00K | |
| Cash from Operations | -29.52M | -22.45M | -23.21M | -23.44M | |
| Capital Expenditure | -299.00K | -605.00K | -103.00K | -279.00K | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | -299.00K | -605.00K | -103.00K | -279.00K | |
| Total Debt Issued | -- | 0.00 | 0.00 | 24.22M | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | 127.88M | 63.00K | 226.00K | 365.00K | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | 70.79M | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -500.00K | -594.00K | -2.38M | -- | |
| Cash from Financing | 127.38M | 70.26M | -2.15M | 24.58M | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 97.56M | 47.21M | -25.46M | 865.00K | |